Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions
Back to News
AlphaMaven Alternative Investment News
Hedge Fund Private Equity

Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions

dealbreaker
4 months ago
66 views
When Novartis agreed to buy RNA therapies developer Avidity Biosciences last fall, the companies said the plan was to spin out Avidity’s cardiology assets into a separate, publicly traded company. That biotech has launched bearing the name Atrium Therapeutics.Atrium’s debut followed Novartis’s Friday close of its $12 billion acquisition of Avidity, which includes two late-clinical programs for rare neuromuscular disorders. The pipeline Atrium inherits consists of two precision cardiology candida...

Continue Reading

Sign up for FREE to read the full article and access 132K+ alternative investment headlines.

Create Free Account Login

Not a member yet?

Why AlphaMaven

The Premier Alternative
Investment Platform

Research & Due Diligence for Qualified Investors

Free Membership for Qualified Investors & Industry Participants
Personalized Content
Breaking News 24/7
Daily Newsletter & Indices
Investment Listings
Company & Contact Directory
Member Publications
Alpha University Videos
AUM Accelerator Program
Due Diligence, Webinars, Events & LeaderBoards
145K+
News & Posts
24K+
Investor Profiles
24/7
Coverage
Sign Up Now

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.